Tentt

Novartis to Acquire Pikavation Therapeutics for $3B

Announced
HealthcareMerger

Deal Overview

Novartis AG has entered into a definitive agreement to acquire Pikavation Therapeutics, Inc. from Synnovation Therapeutics, Inc. for $3 billion. The transaction is structured as a merger and is at the announced stage.

The excerpt provides the deal consideration and the two counterparties, without additional operational or timing details beyond the agreement status.

Key Details

Transaction
Novartis acquires Pikavation Therapeutics
Deal Size
Over $100M
Reported Value
$3 billion

Source

Read full article on news.google.com

via GN - entered into definitive agreement · March 20, 2026

Powered by Tentt

Source healthcare deals for your firm

Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.

Book a 30-min intro call